Comment: Pancreatic cancer survival extended by over a year with chemotherapy regimen

Bookmark and Share
Published: 4 Jun 2018
Views: 771
Rating:
Save
Dr Andrew Epstein and Prof Richard Schilsky

Dr Andrew Epstein and Prof Richard Schilsky comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from a phase III randomised trial in which patients with surgically resected pancreatic cancer were treated with mFOLFIRINOX.

For more on these results, watch Dr Conroy present in the press conference here, watch Dr Conroys interview with ecancer here or read the news coverage here.